Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.

about

Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.

P2860

Q30248992-A247BCA1-AB36-4DB1-A207-A81675112168 Q38970509-B0973429-9B04-4676-ABBB-4A45C32DF106

P2860

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.

Item

http://www.wikidata.org/entity/Q39730219

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Factors associated with virolo ...... enced HIV-1-infected patients.

@en

Factors associated with virolo ...... enced HIV-1-infected patients.

@nl

type

Item

label

Factors associated with virolo ...... enced HIV-1-infected patients.

@en

Factors associated with virolo ...... enced HIV-1-infected patients.

@nl

prefLabel

Factors associated with virolo ...... enced HIV-1-infected patients.

@en

Factors associated with virolo ...... enced HIV-1-infected patients.

@nl

P1476

Factors associated with virolo ...... enced HIV-1-infected patients.

@en

P2093

A Simon

http://www.w3.org/2001/XMLSchema#string

A-G Marcelin

http://www.w3.org/2001/XMLSchema#string

C Charpentier

http://www.w3.org/2001/XMLSchema#string

C Soulie

http://www.w3.org/2001/XMLSchema#string

D Descamps

http://www.w3.org/2001/XMLSchema#string

E K Alidjinou

http://www.w3.org/2001/XMLSchema#string

F Ajana

http://www.w3.org/2001/XMLSchema#string

G Peytavin

http://www.w3.org/2001/XMLSchema#string

L Bocket

http://www.w3.org/2001/XMLSchema#string

M Lê

http://www.w3.org/2001/XMLSchema#string

P2860

CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Maraviroc for previously treated patients with R5 HIV-1 infection

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.

Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.

High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.

P304

2651-2653

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKW167

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christine Katlama

P577

2016-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27234463

http://www.w3.org/2001/XMLSchema#string

P921

virology

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.

about

P2860

P2860

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921